respiratori
syncyti
viru
rsv
common
caus
respiratori
infect
infant
vaccin
avail
report
recombin
aikc
measl
vaccin
express
rsv
g
f
protein
subgroup
mvaikrsvg
f
investig
rsv
vaccin
candid
mvaikrsvg
f
origin
ts
phenotyp
express
rsvg
f
protein
crossreact
neutral
antibodi
rsv
subgroup
b
detect
cotton
rat
immun
intramuscularli
mvaikrsvf
mvaikrsvg
cotton
rat
infect
rsv
rsv
recov
lung
histopatholog
find
compat
interstiti
pneumonia
demonstr
thicken
alveolar
wall
infiltr
mononuclear
cell
cotton
rat
immun
mvaikrsvf
challeng
homolog
rsv
subgroup
infecti
rsv
recov
mild
inflamm
note
without
rsv
antigen
express
challeng
subgroup
b
protect
efficaci
decreas
cotton
rat
immun
mvaikrsvg
challeng
rsv
subgroup
low
level
infecti
viru
recov
lung
challeng
subgroup
b
protect
effect
demonstr
demonstr
larg
amount
rsv
antigen
bronchialepitheli
cell
mvaikrsvf
promis
candid
protect
effect
confirm
monkey
model
human
respiratori
syncyti
viru
rsv
member
famili
paramyxovirida
order
mononegaviral
paramyxovirida
consist
two
subfamili
paramyxovirina
pneumovirina
classifi
genu
pneumoviru
rsv
character
nonseg
neg
sens
singlestrand
rna
genom
approxim
nucleotid
member
paramyxoviru
famili
similar
structur
characterist
viral
particl
rsv
surround
lipid
bilay
two
viral
glycoprotein
g
f
involv
attach
fusion
entri
cell
infect
g
protein
alway
requir
infect
cell
fusion
express
f
protein
alon
lead
cell
fusion
rsv
first
isol
two
antigen
differ
subgroup
b
cocircul
rsv
common
caus
lower
respiratori
infect
infant
young
children
worldwid
respons
varieti
ill
includ
pneumonia
case
bronchiol
case
among
hospit
children
peak
seriou
rsv
infect
month
age
children
experi
rsv
infect
two
year
age
infect
caus
seriou
ill
especi
babi
born
prematur
chronic
lung
diseas
congenit
heart
diseas
rsv
also
caus
lower
respiratori
tract
infect
elderli
immunocompromis
host
global
annual
morbid
mortal
rsv
estim
million
death
respect
recent
studi
immun
respons
rsv
show
import
innat
immun
regul
adapt
immun
respons
adapt
immun
gener
consid
effect
due
neutral
antibodi
nt
cellular
immun
respons
clearanc
virus
influenc
innat
inflammatori
respons
secretori
nt
antibodi
gener
repeat
infect
rsv
although
respons
weak
young
infant
presenc
igg
antibodi
lung
shown
reduc
viral
load
even
natur
infect
provid
longterm
protect
immun
reinfect
young
infant
human
monoclon
antibodi
f
protein
avail
prophylaxi
rsv
reduc
seriou
diseas
highrisk
infant
epidem
howev
high
medic
cost
monthli
administr
mean
great
need
develop
rsv
vaccin
sever
obstacl
develop
rsv
vaccin
aluminiumprecipit
formalininactiv
rsv
vaccin
firsv
develop
prevent
infect
fact
symptom
exacerb
among
recipi
subsequ
infect
rsv
firsv
gener
bind
antibodi
without
neutral
activ
denatur
f
protein
induc
cytotox
cell
lymphocyt
ctl
activ
sever
strategi
adopt
develop
subunit
vaccin
live
attenu
vaccin
convent
method
clone
select
ts
mutant
genet
modifiedstrain
revers
genet
vaccinia
viru
vectorbas
recombin
vaccin
recent
method
direct
manipul
genom
rna
mononegaviral
establish
known
infecti
cdna
clone
system
transcript
replic
minigenom
rna
driven
viral
protein
coexpress
plasmid
helper
virus
use
system
infecti
recombin
virus
retriev
authent
fullsiz
genom
cdna
revers
genet
techniqu
power
tool
basic
research
viral
properti
characterist
viral
protein
mechan
replic
transcript
pathogenesi
also
practic
purpos
develop
new
vaccin
viral
vector
vectorbas
recombin
vaccin
human
parainfluenza
viru
type
iii
hpiv
iii
vectorbas
sendai
viru
vectorbas
vaccin
evalu
current
measl
vaccin
use
throughout
world
attenu
edmonston
strain
classifi
genotyp
aikc
strain
measl
vaccin
develop
japan
edmonston
strain
plaqu
clone
passag
sheep
kidney
cell
chicken
embryon
cell
c
show
optim
growth
c
littl
growth
c
safeti
immunogen
aikc
measl
vaccin
establish
clinic
trial
revers
genet
aikc
live
attenu
vaccin
perform
studi
recombin
aikc
mv
vaccin
strain
encod
rsv
g
f
protein
construct
immunogen
protect
effect
rsv
investig
cotton
rat
immun
recombin
measl
vaccin
express
rsv
g
f
protein
aikc
seed
strain
vaccin
product
use
wildtyp
strain
rsv
subgroup
b
isol
cell
patient
long
wildtyp
strain
use
neutral
test
nt
rsv
subgroup
b
cell
maintain
eagl
mem
sigmaaldrich
dorset
uk
supplement
fetal
bovin
serum
fb
vero
cell
maintain
eagl
mem
supplement
fb
cell
marmoset
b
cell
line
maintain
medium
sigmaaldrich
dorset
uk
supplement
fb
media
supplement
mm
lglutamin
iuml
penicillin
gml
streptomycin
genom
rna
extract
clinic
isol
subgroup
b
rsv
genom
amplifi
rtpcr
viral
rna
first
convert
cdna
use
cdna
primer
rsv
g
gene
amplifi
amplifi
bp
rsv
f
gene
amplifi
amplifi
bp
f
g
gene
clone
use
two
restrict
enzym
nco
underlin
sequenc
schemat
diagram
strategi
use
construct
recombin
cdna
plasmid
shown
fig
full
length
plasmid
divid
two
part
previous
report
first
half
contain
n
p
f
gene
leader
sequenc
pac
site
nucleotid
posit
aikc
genom
second
half
contain
h
l
region
pac
site
posit
aikc
genom
trailer
sequenc
fulllength
cdna
pmvaik
construct
use
two
plasmid
clone
vector
rsv
genom
construct
posit
sac
ii
rsv
g
f
pcr
product
digest
nco
ligat
result
respect
digest
sac
ii
pac
ligat
pmvaik
fulllength
infecti
cdna
clone
pmvaikrsvg
pmvaikrsvf
construct
monolay
cell
plate
infect
vaccinia
viru
pol
express
rna
polymeras
pol
deriv
highli
attenu
host
rangerestrict
vaccinia
viru
ankara
strain
open
read
frame
n
p
l
gene
clone
downstream
promot
pbluescript
sk
express
plasmid
construct
h
adsorpt
cell
wash
optimem
gibco
grand
island
ny
us
transfect
g
g
g
g
pmvaikrsv
reagent
miru
bio
corpor
us
incub
c
h
medium
contain
transfect
reagentplasmid
complex
replac
fresh
mem
suppli
fb
transfect
cell
incub
c
co
day
day
cell
detach
cocultur
cell
demonstr
cytopath
effect
cpe
observ
supernat
cell
lysat
harvest
stock
examin
viral
growth
cell
infect
mvaik
mvaikrsvg
mvaikrsvf
moi
plate
place
temperatur
c
cultur
fluid
obtain
day
cultur
infect
titer
examin
express
tcid
ml
cell
cell
infect
mvaik
mvaikrsvg
mvaikrsvf
moi
plate
cultur
two
day
c
cell
collect
subject
indirect
immunostain
without
fixat
detect
surfac
express
polyclon
antibodi
rsv
rais
goat
abcam
cambridg
uk
use
cell
incub
h
c
cell
wash
extens
phosphatebuff
salin
tween
pbst
stain
second
antibodi
goat
igg
conjug
fitc
rais
rabbit
vector
laboratori
burlingam
ca
us
thereaft
mous
monoclon
antibodi
mv
ha
protein
kindli
suppli
dr
sato
nation
institut
infecti
diseas
japan
use
follow
second
antibodi
mous
igg
conjug
rhodamin
rais
goat
rockland
immunochem
gilbertsvil
pa
us
vero
cell
infect
mvaik
mvaikrsvf
mvaikrsvg
infect
rsv
subgroup
long
strategi
construct
recombin
aikc
genom
cdna
rsv
protein
gene
recombin
aikc
viral
cdna
express
rsv
g
f
protein
construct
base
aikc
cdna
pmvaik
construct
clone
foreign
gene
asc
site
introduc
ad
ggcgcg
posit
aikc
sequenc
ad
nco
inot
fragment
rsv
g
f
clone
design
uniqu
restrict
enzym
site
sac
ii
pac
site
locat
p
gene
f
h
gene
dna
fragment
sac
ii
pac
site
insert
pmvaik
use
sac
ii
pac
site
recombin
plasmid
construct
design
pmvaikrsvg
pmvaikrsvf
respect
strain
plate
cultur
supernat
collect
cell
freezethaw
total
protein
g
supernat
cell
lysat
appli
sampl
subject
western
blot
briefli
sdspage
protein
transfer
membran
immobilon
millipor
danver
us
membran
wash
pbst
incub
rsv
polyclon
antibodi
rais
goat
wash
incub
donkey
antigoat
igg
h
l
conjug
hors
radish
peroxidas
hrp
final
reaction
perform
dab
substrat
kit
peroxidas
vector
laboratori
burlingam
ca
us
use
recommend
manufactur
cultur
medium
vero
cell
infect
mvaikrsvg
f
collect
fraction
sucros
discontinu
gradient
ultracentrifug
fraction
obtain
top
gradient
sucros
fraction
sucros
fraction
sucros
fraction
electrophores
analyz
western
blot
use
rsv
polyclon
antibodi
monoclon
antibodi
mv
n
protein
sixweekold
cotton
rat
purchas
harlan
indianapoli
us
charl
river
usa
five
cotton
rat
group
immun
intramuscularli
tcid
mvaik
mvaikrsvg
mvaikrsvf
serum
sampl
obtain
immedi
week
immun
cotton
rat
immun
mvaikrsvg
f
boost
dose
week
serum
sampl
collect
one
week
reimmun
week
neutral
test
nt
rsv
perform
plaqu
reduct
assay
use
long
strain
wildtyp
isol
subgroup
b
briefli
serum
sampl
serial
dilut
start
dilut
mix
equal
volum
rsv
pfu
mem
h
room
temperatur
mixtur
inocul
monolay
cell
plate
plate
incub
h
c
co
overlaid
mem
supplement
glutamin
antibiot
fetal
bovin
serum
agar
incub
six
day
c
co
cell
fix
formalin
agar
remov
cell
stain
neutral
red
plaqu
number
count
nt
antibodi
titer
calcul
reciproc
serum
dilut
show
reduct
plaqu
number
particl
agglutin
pa
test
gelatin
particl
coat
purifi
measl
viru
antigen
serodia
measl
fuji
rebio
tokyo
japan
sera
serial
dilut
twofold
start
dilut
serum
dilut
mix
equal
volum
gelatin
particl
detect
agglutin
accord
recommend
manufactur
pa
antibodi
titer
express
reciproc
serum
dilut
induc
particl
agglutin
cotton
rat
sacrif
day
immun
mvaikrsvg
f
sampl
liver
kidney
spleen
lung
thymu
nasal
turbin
obtain
detect
mv
genom
tissu
homogen
total
rna
tabl
primer
probe
sequenc
detect
mvaik
n
gene
rsv
n
gene
taqman
realtim
pcr
sequenc
tabl
seven
weekold
cotton
rat
immun
intramuscularli
mvaikrsvf
mvaikrsvg
five
week
later
challeng
ml
rsv
subgroup
b
sacrif
four
day
challeng
nasal
wash
bal
nasal
turbin
lung
tissu
obtain
lung
sampl
divid
two
portion
one
patholog
examin
anoth
recov
infect
particl
rsv
genom
tissu
homogen
ml
volum
serial
dilut
homogen
sampl
place
cell
overlaid
mem
fb
agar
plaqu
number
count
incub
six
day
c
infect
express
number
plaqu
rna
extract
nasal
wash
bal
nasal
turbin
lung
homogen
cdna
synthes
reversetranscrib
realtim
pcr
done
posit
rsv
n
genom
use
primer
taqman
probe
list
tabl
rsv
genom
copi
number
calcul
refer
linear
regress
assay
serial
dilut
correspond
plasmid
lung
inflat
normal
volum
formalin
submerg
formalin
overnight
fixat
fix
tissu
embed
paraffin
section
stain
hematoxylineosin
immunostain
perform
use
four
clone
blend
monoclon
antibodi
rsv
p
f
n
protein
adb
serotec
uk
antimous
igg
conjug
hrp
cultur
supernat
harvest
day
cultur
infect
examin
mvaikrsvg
mvaikrsvf
show
tcid
ml
c
mvaikrsvf
grew
littl
c
howev
infecti
viru
detect
c
ts
phenotyp
maintain
fig
cultur
medium
cell
lysat
examin
express
rsv
g
f
western
blot
result
shown
fig
live
vector
viru
mvaik
rsv
use
neg
posit
control
rsv
g
f
protein
detect
supernat
cell
lysat
infect
mvaikrsvf
mvaikrsvg
similar
infect
rsv
fig
panel
cultur
fluid
collect
fraction
sucros
discontinu
gradient
ultracentrifug
fraction
obtain
top
gradient
sucros
fraction
sucros
fraction
sucros
fraction
electrophores
analyz
western
blot
use
rsv
polyclon
antibodi
monoclon
antibodi
appear
cpe
cultur
media
replac
serum
free
medium
vpsfm
ml
cultur
medium
harvest
l
pb
ad
plate
cell
freezethaw
cell
lysat
clarifi
western
blot
initi
supernat
cell
lysat
subject
experi
stain
polyclon
antibodi
rsv
b
infecti
particl
obtain
sucros
discontinu
gradient
ultracentrifug
fraction
obtain
top
gradient
sucros
fraction
sucros
fraction
sucros
fraction
analyz
western
blot
use
rsv
polyclon
antibodi
monoclon
antibodi
mv
n
protein
mv
n
protein
rsv
g
f
detect
fraction
wherea
mv
n
protein
detect
fraction
fig
panel
b
accordingli
rsv
g
f
protein
translat
insert
gene
consid
incorpor
mv
particl
recombin
virus
mvaikrsvg
mvaikrsvf
inocul
cotton
rat
confirm
immunogen
intramuscularli
insert
rsv
g
f
protein
five
cotton
rat
immun
mvaik
mvaikrsvg
mvaikrsvf
studi
group
serum
sampl
obtain
week
immun
result
shown
fig
pa
antibodi
mv
detect
three
week
immun
anim
high
level
pa
antibodi
maintain
week
immun
mvaik
mvaikrsvg
mvaikrsvf
two
rat
reimmun
week
first
immun
sera
obtain
one
week
reimmun
group
pa
antibodi
increas
mvaikrsvg
group
mvaikrsvf
group
pa
antibodi
mv
increas
reimmun
four
eightfold
result
nt
antibodi
rsv
shown
fig
cotton
rat
immun
mvaikrsvg
nt
antibodi
rsv
subgroup
detect
one
week
immun
mean
titer
began
decreas
week
immun
mean
nt
titer
rsv
subgroup
decreas
undetect
level
week
immun
mvaikrsvf
group
nt
antibodi
rsv
subgroup
detect
one
week
immun
anim
mean
titer
high
titer
observ
week
mean
level
antibodi
maintain
week
experi
rsv
sourc
recombin
mvaikrsvf
mvaikrsvg
deriv
rsv
subgroup
wild
type
cross
immun
rsv
subgroup
b
investig
cotton
rat
immun
mvaikrsvf
nt
antibodi
rsv
subgroup
b
detect
week
mean
titer
maintain
week
howev
crossreact
antibodi
rsv
subgroup
b
detect
cotton
rat
immun
mvaikrsvg
cotton
rat
immun
mvaikrsvf
nt
antibodi
rsv
subgroup
b
increas
reimmun
two
fold
significantli
rat
immun
mvaikrsvg
nt
antibodi
rsv
subgroup
boost
undetect
level
reimmun
rsv
subgroup
b
detect
peak
respons
rsv
observ
five
week
immun
three
cotton
rat
immun
mvaikrsvf
mvaikrsvg
challeng
homolog
rsv
subgroup
long
strain
heterolog
subgroup
b
wildtyp
infecti
viru
recov
nasal
wash
bal
rsv
genom
detect
rsn
genom
copi
number
slightli
lower
immun
group
signific
data
shown
recoveri
infecti
viru
genom
copi
number
lung
tissu
shown
fig
pfu
infecti
viru
recov
mg
lung
tissu
two
cotton
rat
control
group
challeng
rsv
subgroup
infecti
viru
recov
three
cotton
rat
immun
mvaikrsvf
meanwhil
pfu
infecti
viru
recov
cotton
rat
immun
mvaikrsvg
challeng
rsv
subgroup
b
pfu
rsv
recov
lung
infect
rsv
subgroup
b
nonimmun
rat
cotton
rat
immun
mvaikrsvf
viru
titer
slightli
lower
pfu
pfu
lung
tissu
cotton
rat
immun
mvaikrsvg
signific
reduct
rsv
n
gene
copi
number
histopatholog
examin
lung
tissu
obtain
four
day
challeng
rsv
subgroup
b
result
stain
immunostain
rsv
antigen
shown
fig
nonimmun
rat
challeng
rsv
subgroup
show
promin
interstiti
pneumonia
fig
recoveri
rsv
infecti
viru
genom
copi
number
challeng
rsv
subgroup
b
three
cotton
rat
investig
normal
control
group
nonimmun
group
group
immun
mvaikrsvf
mvaikrsvg
anim
nonimmun
group
group
immun
mvaikrsvf
mvaikrsvg
challeng
pfu
homolog
rsv
long
strain
wildtyp
subgroup
b
five
week
later
viru
infect
monitor
lung
homogen
rsv
infect
shown
pfu
mg
lung
tissu
g
total
rna
lung
tissu
use
realtim
pcr
column
repres
individu
result
panel
thicken
alveolar
wall
infiltr
inflammatori
mononuclear
cell
rsv
antigen
bronchial
epitheli
cell
panel
cotton
rat
immun
mvaikrsvf
show
mild
inflamm
panel
though
section
normal
without
rsv
antigen
bronchial
tissu
rsv
challeng
subgroup
panel
cotton
rat
immun
mvaikrsvg
moder
interstiti
pneumonia
observ
small
amount
rsv
antigen
panel
challeng
rsv
subgroup
b
histolog
find
nonimmun
rat
challeng
subgroup
b
similar
result
challeng
rsv
subgroup
result
immunostain
shown
larg
amount
rsv
antigen
detect
nonimmun
rat
panel
small
amount
rsv
antigen
fig
pulmonari
histopatholog
cotton
rat
challeng
rsv
subgroup
b
cotton
rat
immun
intramuscularli
mvaikrsvf
panel
mvaikrsvg
panel
challeng
five
week
later
rsv
subgroup
panel
subgroup
b
panel
sacrif
four
day
challeng
histolog
examin
perform
stain
lung
tissu
panel
result
immunostain
bronchiolar
region
shown
panel
immunostain
perform
use
four
clone
blend
monoclon
antibodi
rsv
p
f
n
protein
antimous
igg
conjug
hrp
stain
immunostain
normal
control
shown
panel
detect
mvaikrsvf
group
panel
comparison
mvaikrsvg
group
panel
find
rsv
antigen
well
correl
result
recoveri
infecti
viru
lung
tissu
inocul
viru
would
clear
demonstr
mild
patholog
find
rat
immun
mvaikrsvf
rsv
clinic
import
caus
respiratori
tract
infect
especi
among
highrisk
infant
immunocompromis
host
elderli
despit
seriou
diseas
burden
licens
vaccin
rsv
initi
effort
develop
vaccin
involv
firsv
unexpectedli
enhanc
diseas
clinic
trial
rsvnaiv
children
firsv
fail
induc
secretori
iga
respons
pareter
administr
without
induc
ctl
respons
seriou
drawback
inactiv
vaccin
defeat
f
protein
would
induc
respons
aluminiumprecipit
vaccin
induc
respons
allerg
reaction
vaccin
would
caus
reaction
sever
subunit
vaccin
investig
fail
gener
effect
antibodi
live
attenu
vaccin
advantag
induc
humor
cellular
immun
respons
similar
natur
infect
temperaturesensit
ts
coldadapt
ca
rsv
vaccin
strain
develop
convent
attenu
method
last
year
cautiou
deliber
progress
made
toward
develop
rsv
vaccin
use
variou
experiment
approach
includ
live
attenu
strain
vectorbas
viral
protein
subunit
vaccin
candid
balanc
safeti
immunogen
key
issu
develop
live
attenu
vaccin
ts
rsv
vaccin
candid
result
insuffici
attenu
caus
similar
respiratori
ill
base
vaccin
candid
ts
phenotyp
sever
recombin
vaccin
candid
develop
delet
sh
gene
gene
mutat
revers
genet
recombin
rsv
vaccin
induc
suffici
immun
respons
chimpanze
anoth
approach
involv
applic
revers
genet
express
rsv
protein
recombin
vectorbas
vaccin
first
vectorbas
candid
evalu
use
vaccinia
viru
recombin
express
rsv
f
g
highli
immunogen
induc
protect
mous
provid
inconsist
protect
chimpanze
mva
strain
vacciniabas
recombin
express
rsv
g
f
protein
immunogen
rodent
rhesu
monkey
model
sever
vectorbas
live
vaccin
platform
establish
use
hpiviii
sendai
viru
preced
experi
f
protein
known
effect
g
experi
clinic
usag
hpiviiibas
recombin
vaccin
poorli
immunogen
human
clinic
trial
report
revers
genet
use
aikc
live
attenu
measl
vaccin
develop
recombin
measl
viru
vectorbas
vaccin
establish
use
schwartz
strain
express
west
nile
viru
well
schwartz
strain
aikc
measl
vaccin
attenu
vaccin
strain
ts
phenotyp
safeti
immunogen
confirm
thu
report
aikc
use
live
viru
vaccinevector
express
rsv
g
f
protein
confirm
indirect
immunostain
cell
infect
mvaikrsvg
f
polyclon
monoclon
antibodi
f
protein
western
blot
g
f
protein
detect
cultur
medium
cell
lysat
cell
infect
mvaikrsvg
f
rsv
g
f
protein
consid
incorpor
mv
particl
theoret
bind
site
mv
protein
mv
envelop
protein
bound
protein
genet
stabil
vaccin
candid
examin
insert
gene
rsv
g
f
stabl
even
passag
recombin
measl
viru
mvaik
trigger
immun
respons
three
week
vaccin
cotton
rat
level
antibodi
maintain
week
observ
immun
mvaikrsvg
f
investig
viral
growth
sampl
nasal
turbin
lung
thymu
spleen
liver
kidney
bone
marrow
obtain
day
immun
infecti
viru
recov
total
rna
extract
rtreal
time
pcr
perform
detect
measl
n
gene
realtim
pcr
mv
genom
detect
thymu
cotton
rat
immun
mvaik
mvaikrsvg
mvaikrsvf
data
shown
infecti
viru
recov
inguin
superfici
lymph
node
three
day
infect
previou
studi
nt
antibodi
titer
rsv
investig
use
rsv
long
subgroup
wildtyp
subgroup
b
mvaikrsvg
mvaikrsvf
induc
product
nt
antibodi
rsv
subgroup
one
week
vaccin
cotton
rat
antibodi
titer
higher
immun
mvaikrsvf
mvaikrsvg
rsv
distinctli
differ
subgroup
b
g
f
gene
subgroup
use
studi
therefor
cross
reaction
nt
subgroup
b
investig
mvaikrsvg
gener
nt
antibodi
rsv
subgroup
b
mvaikrsvf
induc
product
crossreact
nt
antibodi
rsv
subgroup
b
predict
amino
acid
sequenc
rsv
f
protein
use
studi
exhibit
homolog
among
f
protein
subgroup
strain
comparison
subgroup
b
strain
predict
amino
acid
sequenc
rsv
g
protein
homolog
among
subgroup
strain
comparison
subgroup
b
thu
f
protein
rel
conserv
subgroup
b
g
protein
rsv
variabl
thought
suitabl
vaccin
antigen
recent
human
monoclon
antibodi
rsv
f
protein
use
prevent
seriou
rsv
infect
young
infant
cardiac
pulmonari
disord
low
birth
weight
born
prematur
studi
recombin
mvaikrsvg
f
administ
intramuscularli
induc
suffici
nt
antibodi
secretori
iga
antibodi
ctl
respons
examin
protect
challeng
homolog
rsv
subgroup
nonimmun
cotton
rat
pfu
infecti
viru
recov
mg
lung
tissu
four
day
rsv
challeng
immun
mvaikrsvf
protect
without
recoveri
infecti
viru
lung
tissu
demonstr
interstiti
pneumonia
cross
reactiv
nt
antibodi
demonstr
immun
mvaikrsvf
protect
effect
suffici
subgroup
b
demonstr
slightli
lower
level
approxim
nonimmun
control
recoveri
infecti
viru
protect
effect
mvaikrsvg
poor
comparison
mvaikrsvf
similar
serolog
respons
experiment
anim
model
transgen
mice
express
human
knock
type
interferon
ifn
receptor
gene
use
evalu
immunogen
recombin
mv
vaccin
candid
produc
use
west
nile
viru
sar
corona
viru
hepat
b
viru
hiv
effici
immun
respons
report
ifn
system
import
signal
innat
immun
case
rsv
vaccin
candid
innat
immun
modifi
adapt
immun
therefor
cotton
rat
without
gene
manipul
use
experi
recombin
mv
vaccinebas
vector
practic
limit
time
immun
young
infant
matern
confer
immun
would
interfer
vaccin
effect
field
trial
aikc
gave
effici
seroconvers
induct
cellmedi
immun
even
vaccin
given
age
six
month
demonstr
seroconvers
rate
overcom
matern
confer
immun
safeti
similarli
confirm
suggest
evid
immunesuppress
rsv
infect
observ
even
six
month
age
therefor
mvaikrsvf
would
applic
six
month
provid
protect
immun
rsv
measl
especi
develop
countri
effect
protect
rsv
infect
intranas
administr
desir
experi
intranas
administr
aikc
vaccin
previou
experi
recombin
mvaik
induc
serum
nt
mv
intranas
administr
strict
ts
phenotyp
cotton
rat
model
high
bodi
temperatur
therefor
compar
studi
plan
investig
immunogen
challeng
test
monkey
immun
mvaikrsvf
conclus
new
mv
vaccinestrainbas
rsv
vaccin
candid
demonstr
confer
protect
rsv
cotton
rat
xenogen
recombin
might
induc
simultan
protect
immun
backbonemv
insertedrsv
infect
recombin
mvaik
express
rsv
f
protein
promis
candid
protect
effect
confirm
monkey
model
consid
immun
rout
